Year: 2020

VANCOUVER, British Columbia, Nov. 10, 2020 (GLOBE NEWSWIRE) — Sabina Gold & Silver Corp. (“Sabina”) or (the “Company”) (SBB – TSX/ SGSVF – OTCQX) reports the interim financial results for the quarter ended September 30, 2020.“During the quarter, under a rigid COVID 19 operational framework, the Company commenced pre-construction activities including extension of the permanent air strip at Goose, construction of a road network at the Goose Property and commencement of the box cut to prepare for the Goose underground exploration decline construction in 2021,” said Bruce McLeod, the Company’s President & CEO. “The Company also recommenced its 2020 drilling and field campaign, targeting the high-grade underground at Umwelt, resulting in defining the V2 Zone, as well as drilling at Llama and other field programs. Final...

Key financial highlightsRevenue growth of 24.0 % over the same period of the previous fiscal year reached $35.0 M for the first quarter of fiscal year 2021;Gross profit margin (%) before depreciation and amortization expenses of 27.1 % for the first quarter of fiscal year 2021, compared to 23.8 % for the first quarter of previous fiscal year;Adjusted EBITDA1 reached $3.5 M, or 9.9 % of revenues, for the first quarter of fiscal year 2021 compared to $1.6 M, or 5.8 % of revenues, for the comparable quarter of previous fiscal year;Net earnings amounted to $1.0 M for the first quarter of fiscal year 2021, compared to a net loss of ($1.0 M) for the comparable quarter of previous fiscal year;Solid financial position with a ratio net debt/adjusted EBITDA1 of 0.92 at the end of the quarter;Cash flows from operating activities generated $1.3 M...

Faits saillantsCroissance des revenus de 24,0 %, par rapport à la même période de l’exercice financier précédent, pour atteindre 35,0 M $ pour le premier trimestre de l’exercice financier 2021;Marge bénéficiaire brute avant amortissement (%) représente 27,1 % pour le premier trimestre de l’exercice financier 2021, comparativement à 23,8 % pour le premier trimestre de l’exercice financier précédent;BAIIA ajusté1 de 3,5 M $, ou 9,9 % des revenus, pour le premier trimestre de l’exercice financier 2021, comparativement à 1,6 M $ ou 5,8 % des revenus, pour le trimestre comparable de l’exercice financier précédent;Bénéfice net de 1,0 M $ au premier trimestre de l’exercice financier 2021, contre une perte nette de (1,0 M $) pour le trimestre comparable de l’exercice financier précédent;Situation financière solide avec un ratio dette nette/BAIIA...

Phase 1 trials evaluating CTI-1601 as a treatment for Friedreich’s ataxia on track for topline data in 1H 2021Received orphan drug designation for CTI-1601 from the European CommissionCash, cash equivalents, and marketable securities of $102.3 million as of September 30, 2020BALA CYNWYD, Pa., Nov. 10, 2020 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2020 operating and financial results.“I am very pleased with the progress Larimar has made over the past few months, as we achieved key clinical, regulatory, and corporate milestones that have left us well positioned for continued growth,” said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics. “In the...

LOS ANGELES, Nov. 10, 2020 (GLOBE NEWSWIRE) — via NetworkWire – Cannabis Strategic Ventures (OTCQB:NUGS) (“NUGS” or the “Company”), an emerging leader in the U.S. cannabis marketplace, is excited to announce performance data for the three months ended Sept. 30, 2020, which featured robust growth and broad expansion in positioning within the rapidly growing California cannabis marketplace.The Company booked over $6.4 million in total sales from cannabis during the three months ended Sept. 30, 2020, which compares with $3.3 million in total sales from cannabis during the three months ended June 30, 2020, a sequential quarterly increase of over 90%, and a year-over-year increase of over 800% compared to the three months ended Sept. 30, 2019.“We saw a terrific quarter come to an end in September, but we are already turning our attention...

Enrollment completed in the 28-day Phase 2 razuprotafib glaucoma trial; topline data expected to be reported in December 2020 or possibly in early January 2021Initiated second clinical trial to evaluate razuprotafib for the prevention and treatment of acute respiratory distress syndrome (“ARDS”) in COVID-19 patients and announced first patient dosing in OctoberFirst patients dosed with razuprotafib in the I-SPY COVID trial to treat ARDS in critically-ill COVID-19 patientsEnded third quarter 2020 with $47.3 million in cash and cash equivalentsConference Call Today, November 10, 2020 at 8:30 a.m. ESTCINCINNATI, Nov. 10, 2020 (GLOBE NEWSWIRE) —  Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as...

EDEN PRAIRIE, Minn., Nov. 10, 2020 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the third quarter ended September 30, 2020.Recent HighlightsRevenue for the third quarter of 2020 was $1.9 million, an increase of 52% compared to the prior year periodIncreased Aquadex™ therapy utilization in existing pediatric hospital accounts; opened 6 new pediatric hospital accountsPartnered with Acute Kidney Injury Critical Care Research Foundation and Watermark Research Partners to initiate a pediatric registry to collect real-world evidence for the use of Aquadex SmartFlow™Announced the Aquadex product line was added to the Federal Supply Schedule, expanding access to all federal agencies and eliminating months of fulfillment process timeHosted two webinars during the quarter, led by:– Dr. David...